Skip to main content

Table 2 Anticoagulation indicators

From: Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients

  Group D Group A Group P
1 week 2 week 1 week 2 week 1 week 2 week
APTT
(24–34 s)
47.3 ± 9.7 50.1 ± 12.2 33.6 ± 4.9 31.8 ± 5.4 29.8 ± 2.3 30.0 ± 2.2
PT
(11–14 s)
16.4 ± 1.9 16.3 ± 1.8 15.4 ± 2.6 15.0 ± 2.3 13.1 ± 0.5 13.0 ± 0.6
F1 + 2
(69–229 pmol/l)
150.4 ± 62.3 159.0 ± 62.1 130.9 ± 40.5 182.0 ± 116.6 230.7 ± 59.9 247.2 ± 76.9
IL-6
(< 8 pg/ml)
2.9 ± 4.2 2.3 ± 1.4 5.1 ± 4.8 3.1 ± 1.9 5.3 ± 6.7 2.4 ± 2.5
hsCRP
(< 0.30 mg/dl)
0.10 ± 0.14 0.11 ± 0.13 0.22 ± 0.21 0.20 ± 0.19 0.19 ± 0.20 0.12 ± 0.16
PTX3
(0.73–5.49 ng/ml)
3.4 ± 3.8 2.9 ± 2.4 3.9 ± 2.8 3.5 ± 2.1 3.3 ± 2.5 3.0 ± 2.3
  1. Normal range of each factor is indicated in parentheses. Data are presented as average ± standard deviation
  2. APTT activated partial thromboplastin time, PT prothrombin time, F1 + 2 prothrombin fragment, IL-6 interleukin 6, hsCRP high sensitivity C-reactive protein, PTX3 pentraxin 3